首頁 > 市場調查報告書 > 製藥

感染疾病

全球外陰陰道念珠菌病治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1342780

全球外陰陰道念珠菌病治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Vulvovaginal Candidiasis Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 177 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，全球外陰陰道念珠菌病治療市場的市場規模將從 2022 年的 42 億美元達到近 69.6 億美元，2023-2030 年研究期間年複合成長率為 6.51%。

外陰陰道念珠菌病治療是針對陰道酵母菌感染（一種常見的真菌感染）的治療。瘙癢、排尿或性交時有燒灼感或不適、腫脹、皮疹和炎症，都是陰道酵母菌感染的症狀。隨著糖尿病病例的增加和人們更頻繁地使用抗生素，外陰陰道念珠菌病的患病率也在增加。通常建議使用抗真菌藥物來治療陰道念珠菌病。

市場動態：

隨著外陰陰道念珠菌病感染的增加以及對治療該病的有效藥物的需求，預計市場將呈成長趨勢。研究和開發、新藥批准和產品上市的顯著增加正在擴大對更好治療選擇的需求，為外陰陰道念珠菌病治療的商業成長創造有利可圖的機會。此外，由於醫療保健和政府投資的增加、醫療保健系統的發展、藥物的可及性以及製藥和生物技術領域的重大技術發展，在預期的時間內，外陰陰道念珠菌病的治療將有很多機會部門。由於缺乏公眾意識、缺乏採用新技術的專業知識以及與診斷和治療方法相關的高成本，預計外陰陰道念珠菌病治療市場將受到阻礙。

該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球外陰陰道念珠菌病治療市場的各個細分市場進行了包容性評估。外陰陰道念珠菌病治療行業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲外陰陰道念珠菌病治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。外陰陰道念珠菌病治療市場的主要參與者包括Astellas Pharma Inc.、Mycovia Pharmaceuticals Inc.、Bayer AG.、Basilea Pharmaceutica Ltd.、Scynexis Inc.、Grupo Ferrer Internacional SA、Pfizer Inc.、Cadila Pharmaceuticals、Bristol-Myers Squibb Company 。本節包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

Covid-19 爆發的影響分析
- 對生產的直接影響
- 供應鍊和市場顛覆
- 對公司和金融市場的財務影響
按生產、進口、出口和需求分類的 COVID-19 影響分析
市場：COVID-19 前 V/S 後
冠狀病毒 (COVID-19) 疫情的預計影響
COVID-19：微觀和宏觀因素分析

第 6 章：全球外陰陰道念珠菌病治療市場分析：按藥物類別

按藥物類別概述
歷史和預測數據
按藥物類別分析
克黴唑
制黴菌素
氟康唑
酮康唑
特比萘芬
特康唑
其他

第 7 章：全球外陰陰道念珠菌病治療市場分析：按給藥途徑

按給藥途徑概述
歷史和預測數據
按給藥途徑分析
口服
靜脈
專題

第 8 章：全球外陰陰道念珠菌病治療市場銷售分析：按配銷通路

按配銷通路分類的概覽
歷史和預測數據
按配銷通路分析
醫院藥房
零售藥房
網上藥房

第 9 章：全球外陰陰道念珠菌病治療市場銷售分析：按地理位置

區域展望銷售分析
簡介銷售分析
北美銷售分析
- 概述、歷史和預測銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 10 章：外陰陰道念珠菌病治療公司的競爭格局

外陰陰道念珠菌病治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 11 章：公司簡介

十大公司股票分析
市場集中度
Astellas Pharma Inc.

公司簡介
公司收入
產品
最近的發展

Mycovia Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Bayer AG.

公司簡介
公司收入
產品
最近的發展

Basilea Pharmaceutica Ltd.

公司簡介
公司收入
產品
最近的發展

Scynexis Inc.

公司簡介
公司收入
產品
最近的發展

Grupo Ferrer Internacional SA

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Cadila Pharmaceuticals

公司簡介
公司收入
產品
最近的發展

Bristol-Myers Squibb Company

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR11219892

The global demand for Vulvovaginal Candidiasis Treatment Market is presumed to reach the market size of nearly USD 6.96 BN by 2030 from USD 4.2 BN in 2022 with a CAGR of 6.51% under the study period 2023 - 2030.

Vulvovaginal candidiasis treatment is a treatment for vaginal yeast infection, a common fungus infection. Itching, a burning feeling or discomfort during urine or intercourse, swelling, rash, and inflammation, are all signs of vaginal yeast infection. As diabetic cases rise and people use antibiotics more frequently, vulvovaginal candidiasis prevalence has grown. Antifungal medicines are typically recommended for the treatment of vaginal candidiasis.

MARKET DYNAMICS:

The market is foreseen to follow a growing trend with the increase in vulvovaginal candidiasis infections and the requirement for effective medicines to treat the condition. The significant increase in research and development, new drug approvals, and product launches are scaling up the demand for better treatment options, creating a profitable opportunity for the commercial growth of vulvovaginal candidiasis treatment. In addition, there will be a lot of opportunities for the treatment of vulvovaginal candidiasis over the anticipated time frame because of an increase in healthcare and government investments, development of the healthcare system, accessibility of medications, and significant technological developments in the pharmaceutical and biotechnology sectors. The market for vulvovaginal candidiasis treatment is estimated to be hampered due to lack of public awareness, expertise in employing new technologies, and high costs related to diagnostic and treatment methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of vulvovaginal candidiasis treatment. The growth and trends of vulvovaginal candidiasis treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the vulvovaginal candidiasis treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Clotrimazole
Nystatin
Fluconazole
Ketoconazole
Terbinafine
Terconazole
Others

By Route Of Administration

Oral
Intravenous
Topical

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Vulvovaginal Candidiasis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the vulvovaginal candidiasis treatment market include Astellas Pharma Inc., Mycovia Pharmaceuticals Inc., Bayer AG., Basilea Pharmaceutica Ltd., Scynexis Inc., Grupo Ferrer Internacional S.A., Pfizer Inc., Cadila Pharmaceuticals, Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . VULVOVAGINAL CANDIDIASIS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route Of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS BY DRUG CLASS

6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Clotrimazole Historic and Forecast Sales by Regions
6.5 Nystatin Historic and Forecast Sales by Regions
6.6 Fluconazole Historic and Forecast Sales by Regions
6.7 Ketoconazole Historic and Forecast Sales by Regions
6.8 Terbinafine Historic and Forecast Sales by Regions
6.9 Terconazole Historic and Forecast Sales by Regions
6.10. Others Historic and Forecast Sales by Regions

7 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1 Overview by Route Of Administration
7.2 Historical and Forecast Data
7.3 Analysis by Route Of Administration
7.4 Oral Historic and Forecast Sales by Regions
7.5 Intravenous Historic and Forecast Sales by Regions
7.6 Topical Historic and Forecast Sales by Regions

8 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

8.1 Overview by Distribution Channel
8.2 Historical and Forecast Data
8.3 Analysis by Distribution Channel
8.4 Hospital Pharmacy Historic and Forecast Sales by Regions
8.5 Retail Pharmacy Historic and Forecast Sales by Regions
8.6 Online Pharmacy Historic and Forecast Sales by Regions

9 . GLOBAL VULVOVAGINAL CANDIDIASIS TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE VULVOVAGINAL CANDIDIASIS TREATMENT COMPANIES

10.1. Vulvovaginal Candidiasis Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF VULVOVAGINAL CANDIDIASIS TREATMENT INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Astellas Pharma Inc.
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Mycovia Pharmaceuticals Inc.
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. Bayer AG.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Basilea Pharmaceutica Ltd.
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Scynexis Inc.
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Grupo Ferrer Internacional S.A.
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Pfizer Inc.
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Cadila Pharmaceuticals
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Bristol-Myers Squibb Company
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments